IRIDEX Granted Patent for MicroPulse™ Technology for Dose Control of Laser Energy During Eye Surgery
August 21, 2010
Submit Comments
On Thursday, IRIDEX announced the issuance of a patent covering its MicroPulse™ technology providing ophthalmologists with fine dose control of laser energy during eye surgery on patients suffering from diabetic retinopathy and other sight-threatening retinal and glaucoma disorders. According to the company, treatments using MicroPulse technology demonstrate favorable outcomes and significantly less damage to healthy retinal structures compared to traditional continuous wave laser treatment.
Laser products such as IRIDEXs’s IQ 577 that incorporate the MicroPulse control technology covered by the recent patent have recently been introduced to the market.
You might also enjoy...
- IRIDEX Granted Patent for Stepped Angled EndoProbe® Laser Handpieces Used in Invasive Eye Surgery
- Icon Biosciences Starting New Trials of Sustained Release Drug Delivery for Post-Op Cataract Patients
- Photocoagulation for Diabetic Retinopathy May Simulate Glaucomatous Damage
- OptiMedica Corp. Presentations at ARVO 2009 to Cover PASCAL Laser Technology
- Acucela Presentations at ARVO 2009
Comments
Jump down to form below to submit your own comments
